Bristol Myers Squibb Reports Positive Phase 2 QUINTESSENTIAL Results for Arlocabtagene Autoleucel
Bristol Myers Squibb Reports Positive Phase 2 QUINTESSENTIAL Results for Arlo-Cel in Heavily Pretreated Multiple Myeloma Bristol Myers Squibb (NYSE: BMY) announced positive Phase 2 results from the registrational QUINTESSENTIAL…
Imdelltra® Plus Imfinzi® Shows Landmark Overall Survival Benefit in First-Line SCLC
IMDELLTRA® Plus IMFINZI® Shows Landmark Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer Amgen (NASDAQ: AMGN) announced landmark results from the Phase 3 DeLLphi-305 study, reporting that the…
Novartis Updates Phase 3 HARBOR Study of Del-desiran in DM1
Novartis Reports HARBOR Phase 3 Study of Del-Desiran in Myotonic Dystrophy Type 1 Misses Primary Endpoint Novartis announced that the global Phase 3 HARBOR study evaluating del-desiran in people living…
Roche’s Enspryng Receives FDA Priority Review for MOGAD
Roche Receives FDA Priority Review for Enspryng in MOGAD Following Positive Phase 3 Results Roche announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a…
Johnson & Johnson Highlights New Neuropsychiatry Data at Psych Congress 2026
Johnson & Johnson to Present 24 Neuropsychiatry Data Sets at Psych Congress 2026 Johnson & Johnson (NYSE: JNJ) will present 24 abstracts featuring clinical trial data and real-world evidence from…
Novo Nordisk STEP Young Data Show 40.4% of Children with Obesity Achieved BMI Below Obesity Threshold
Novo Nordisk Reports Positive Phase 3 STEP Young Results for Semaglutide in Children With Obesity Novo Nordisk has announced the first results from the STEP Young Phase 3 trial evaluating…
Scholar Rock Announces FDA Approval of ISEMBYLD™ for Spinal Muscular Atrophy
Scholar Rock Wins FDA Approval for ISEMBYLD, First Muscle-Targeted Treatment for Spinal Muscular Atrophy Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company focused on developing therapies for rare, severe and…
Strata Mental Health Receives Compass Pathways Grant for COMP360 Provider Training
Strata Mental Health Solutions Awarded Compass Pathways Grant to Develop U.S. Provider Training for COMP360 Strata Mental Health Solutions, an expert-led training and implementation partner focused on preparing clinical networks…
MEDIPAL and JCR Pharmaceuticals Dose First Patient in Phase 1/2 Trial of JR-446 for MPS IIIB
MEDIPAL and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for MPS IIIB MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Co., Ltd. (TSE: 4552) announced that the…
Aptar Pharma Expands Preservative-Free Technology Production in Latin America
Aptar Pharma Transfers Advanced Preservative-Free Production Line to Argentina, Expanding Local Drug Delivery Manufacturing Aptar Pharma, a global provider of drug delivery, dosing, protection technologies and related services, has announced…
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Gossamer Bio Completes 1-for-80 Reverse Stock Split to Support Nasdaq Listing Compliance Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on developing and commercializing seralutinib for pulmonary arterial…
Bausch + Lomb Receives European CE Mark for SeeLyra™ Femtosecond Laser
Bausch + Lomb Receives European CE Mark for Next-Generation SeeLyra Femtosecond Laser Bausch + Lomb Corporation (NYSE/TSX: BLCO), a global eye health company focused on helping people see better and…